alexa Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS+HIPEC) for Recurrent Epithelial Ovarian Cancer (EOC): Indian Experience
ISSN: 1747-0862

Journal of Molecular and Genetic Medicine
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS+HIPEC) for Recurrent Epithelial Ovarian Cancer (EOC): Indian Experience

Somashekhar SP1*, Prasanna G1, Rajshekhar Jaka1, Amit Rauthan2, Murthy HS3 and Sunil Karanth4

1Department of Surgical Oncology, Manipal Comprehensive Cancer Center, Manipal Hospital, Bengaluru, India

2Department of Medical Oncology, Manipal Comprehensive Cancer Center, Manipal Hospital, Bengaluru, India

3Department of anesthesiology, Manipal Hospital, Bengaluru, India

4Department of Critical care, Manipal Hospital, Bengaluru, India

*Corresponding Author:
Somashekhar SP
Department of Surgical Oncology
Consultant Surgical Oncologist and Robotic Surgeon
Manipal Comprehensive Cancer Center, Manipal Hospital
98, HAL Airport Road, Bengaluru-560017, India
Tel: 919845712012
E-mail: [email protected]

Received date: October 27, 2015; Accepted date: June 10, 2016; Published date: June 15, 2016

Citation: Somashekhar SP, Prasanna G, Jaka R, Rauthan A, Murthy HS, et al. (2016) Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS+HIPEC) for Recurrent Epithelial Ovarian Cancer (EOC): Indian Experience. J Mol Genet Med 10:220. doi:10.4172/1747-0862.1000220

Copyright: © 2016 Somashekhar SP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) has been proposed as treatment for recurrent epithelial ovarian carcinoma. We evaluated the outcomes of CRS +HIPEC in recurrent epithelial ovarian cancers, in Indian patients.

Method: In this prospective non-randomized study between February 2013 and January 2015, 26 patients with advanced recurrent EOC, with no extra-abdominal disease treated with secondary CRS+HIPEC in a tertiary care cancer institution, Southern India, were analyzed. Belmonte® hyperthermia (HIPEC) pump with cisplatin 100 mg/m2, 41.5°C to 43°C for 90 minutes, in platinum sensitive cases and doxorubicin 15 mgs/m2 + cisplatin 75 mg/m2 in platinum resistant cases was used.

Result: Among twenty six patients 18 were upfront and 8 were post chemotherapy. Median peritoneal carcinomatosis Index was 9.5 (Range: 3-19). The extent of cytoreduction associated with longer hospital stay (p < 0.001), delayed gastrointestinal recovery (p=0.039), infections (p=0.036), and Acute Respiratory Distress Syndrome (p=0.041). Completeness of cytoreduction score CC0 achieved in 24 and CC1 in 2 patients. Bowel resection required in 34.6%. Diaphragm stripping was required in 30.7% with resection in 7.6%. Median hospital stay was 12 days (range: 10-42 days). No 30 days mortality. Bowel fistula happened in 7.6% cases requiring re-exploration, temporary stomas, and wound related complications in 26%. At median follow-up of eighteen months, 11.5% recurrences (both platinum resistant cases recurred in peritoneal cavity and one patient also in liver parenchyma) and one platinum sensitive patient recurred isolated in peritoneal cavity. One patient died at 5th month of follow up due to pulmonary embolism.

Conclusion: In our Indian study, secondary CRS+HIPEC are shown to be very promising in recurrent epithelial ovarian cancers patients with no extra-abdominal disease and good performance status. And can be done with acceptable morbidity, using dedicated HIPEC machine resulting in good peritoneal control of disease and disease free survival.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords